Revenue Showdown: Teva Pharmaceutical Industries Limited vs Dr. Reddy's Laboratories Limited

Pharmaceutical Giants' Revenue Battle: Dr. Reddy's vs. Teva

__timestampDr. Reddy's Laboratories LimitedTeva Pharmaceutical Industries Limited
Wednesday, January 1, 201413217000000020272000000
Thursday, January 1, 201514818900000019652000000
Friday, January 1, 201615470800000021903000000
Sunday, January 1, 201714080900000022385000000
Monday, January 1, 201814202800000018854000000
Tuesday, January 1, 201915385100000016887000000
Wednesday, January 1, 202017460000000016658000000
Friday, January 1, 202118972200000015878000000
Saturday, January 1, 202221439100000014925000000
Sunday, January 1, 202324587900000015846000000
Monday, January 1, 202427916400000016544000000
Loading chart...

Cracking the code

Revenue Showdown: A Tale of Two Pharmaceutical Giants

In the competitive landscape of pharmaceuticals, Teva Pharmaceutical Industries Limited and Dr. Reddy's Laboratories Limited have been pivotal players. Over the past decade, Dr. Reddy's has consistently outperformed Teva in terms of revenue. From 2014 to 2023, Dr. Reddy's revenue surged by over 110%, peaking at an impressive 279 billion in 2023. In contrast, Teva's revenue saw a decline, dropping by approximately 22% over the same period, with its highest revenue recorded in 2017. This stark contrast highlights Dr. Reddy's strategic growth and market adaptability, while Teva faces challenges in maintaining its market share. The data for 2024 is incomplete, but the trend suggests Dr. Reddy's continued dominance. This revenue showdown underscores the dynamic nature of the pharmaceutical industry and the importance of strategic foresight.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025